ArticleJournal of clinical microbiology2011
Impact of rpoB mutations on reduced vancomycin susceptibility in Staphylococcus aureus.
Article in Journal of clinical microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- Mutations in RNA polymerase that drive the emergence of antibiotic resistance.Current opinion in microbiology · 2026Review
- Current Recommendations, Antibiotic Resistance, and Emerging Treatments for Gram-Positive Ocular Infections in the United States.Antibiotics (Basel, Switzerland) · 2026Review
- Host-driven remodelling of theMicrobiology (Reading, England) · 2026Review
- Methicillin-Resistant Staphylococcus aureus Bacteremia Relapses Show Diverse Genomic Profiles but Convergence in Bacteremia-Associated Genes.The Journal of infectious diseases · 2025Article
- RpoB H481Y Rifampicin Resistance Mutation-Associated Oxidative Stress Sensitivity Reduces the Virulence of Staphylococcus aureus.Microbiology and immunology · 2025Article
- The Role of Rifampin in Prosthetic Joint Infections: Efficacy, Challenges, and Clinical Evidence.Antibiotics (Basel, Switzerland) · 2024Review
- Unraveling novel mutation patterns and morphological variations in two dalbavancin-resistant MRSA strains in Austria using whole genome sequencing and transmission electron microscopy.BMC infectious diseases · 2024Article
- Article
- Molecular Characteristics and Prevalence of Rifampin Resistance inAntibiotics (Basel, Switzerland) · 2023Article
- Teicoplanin associated geneFrontiers in microbiology · 2023Article
- Concordance between Antimicrobial Resistance Phenotype and Genotype ofAntibiotics (Basel, Switzerland) · 2022Article
- Molecular Basis of Non-β-Lactam Antibiotics Resistance inAntibiotics (Basel, Switzerland) · 2022Review
- Risk Factors of Recurrent Infection in Patients with Staphylococcus aureus Bacteremia: a Competing Risk Analysis.Antimicrobial agents and chemotherapy · 2022Article
- Convergent Evolution of Antibiotic Tolerance in Patients with Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia.Infection and immunity · 2022Article
- Genetic Mechanisms of Vancomycin Resistance inAntibiotics (Basel, Switzerland) · 2022Review
- Recombineering in Staphylococcus aureus.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Molecular Characterization of Rifampicin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- Antibacterial Profile of a Microbicidal Agent Targeting Tyrosine Phosphatases and Redox Thiols, Novel Drug Targets.Antibiotics (Basel, Switzerland) · 2021Article
- Identification of a novel tedizolid resistance mutation in rpoB of MRSA after in vitro serial passage.The Journal of antimicrobial chemotherapy · 2021Article
- Molecular Characteristics of Rifampin-Sensitive and -Resistant Isolates and Characteristics ofInfection and drug resistance · 2021Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Of 38 vancomycin-intermediate Staphylococcus aureus (VISA) clinical strains, 27 (71%) possessed a mutation(s) in rpoB encoding the β-subunit of RNA polymerase. Furthermore, 95.6% of the rifampin-resistant mutants obtained from 9 methicillin-resistant S. aureus (MRSA) clinical isolates showed decreased vancomycin susceptibilities. These data indicate the involvement of an rpoB mutation in VISA phenotype expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.